Stop the Spread has fulfilled its charter as of December 2021. This website has been frozen but will remain available through 2022.

Accelerating development and deployment of novel therapies

We believed the most impactful therapeutics lessen the duration and severity of the disease during the early infection phase. We worked to speed the development and deployment of these early interventions that are both readily scalable and affordable. For this reason, we actively supported the use of repurposed drugs with existing safety profiles that will likely move through trials more rapidly.

Accelerating

Deployment and development of novel therapies

We believe the most impactful therapeutics will lessen the duration and severity of the disease during the early infection phase. We are working to speed the development and deployment of these early interventions that are both readily scalable and affordable. For this reason,we actively support the use of repurposed drugs with existing safety profiles that will likely move through trials more rapidly.

Partner with Us

Therapeutics: a critical need

Therapeutics were essential to reduce the burden of COVID-19 while we scaled our vaccine infrastructure and beyond. These therapeutics needed to serve communities in both the US and internationally. As such, we prioritized low-cost and highly scalable generics with existing safety profiles. We worked with private companies and research centers to advance and support new developments.

&

General Motors & Ventec’s Moonshot: 10,000 ventilators a month

Early in the crisis, General Motors and Ventec Life Systems came together to produce critical care ventilators. Given the urgency of the moment, Ventec needed a manufacturing partner who could rapidly scale production of their leading ventilator technology. Enter GM, who quickly repurposed their Kokomo, Indiana factory to partner with Ventec, and will soon ramping up production to 10,000 ventilators per month.

&

Links:

Ventecgm.comMedia KitNew York Times: Article #1New York Times: Article #2
&

Honda & Dynaflo Pumps: Filling The Gap For Critical Ventilator Components

Dynaflo, Inc. produces a sophisticated compressor that is an essential component in critical care medical ventilators.  Due to the pandemic, Dynaflo was asked to scale up production from roughly 300 per month to 10,000 per month.  Dynaflo was able to work with their supply chain to rapidly increase the supply of needed parts, but faced challenges in assembling compressors at scale. Stop the Spread paired them with Honda of America, given expertise in mass production and willingness to help. The partners are now on track to meet their 10,000 compressors a month goal by June. Together, Honda and DynafloPumps are ensuring that ventilators get off the assembly line and into hospitals on time.

&

Links:

Honda press release

I Can Help:

Partner with UsLearn More

Resources for Therapeutics

STS Resources

Therapeutics Factbase

Overview of information related to Therapeutics (September 2020)

PDF
Download

External Resources

Partners

The Fight is In Us

PostEra

Moonshot

PatientWing

Information
AboutResourcesPartner with Us
Critical Needs
VaccinationsTestingVaccinationsHyperlocal
SupportHealth ServicesPPETherapeuticsVentilators
Partner with Us
Any information or other content (“Content”) found on this website is intended to provide an overview of the issues and terminology surrounding COVID-19 and is not intended as professional, medical, or legal advice.  Please seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.  If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.  We do not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on this website.  The Content is for informational and educational purposes only and we provide no representations or warranties.  This website may contain links to third-party sites or content that are not under our control.  We are not responsible for any content on any linked website.

We may collect personal information through the website, such as your name, email, and contact details.  Our primary purpose in collecting personal information is to facilitate the services and Content that you request through the website.  We may also use personal information for various purposes, including to help diagnose problems with the website, to monitor the usage and performance of the website, and to send you materials, updates, and other information.  We may share personal information collected on the website with third parties described on the form where you submitted your personal information, for legal compliance reasons, or as necessary to protect other website users against fraud or illegal activity.  We employ reasonable security measures to protect personal information from becoming disclosed to individuals who are not described on this website.  The website does not currently support “do not track” requests.  We may communicate with you if you provide us with the means to do so, unless you inform us that you do not want to receive communications.  You may contact us using the contact information on the website if you have any additional questions or concerns.